<![CDATA[Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC]]>

Summary

A panel discussion examines emerging endocrine doublet treatments and serial ESR1 biomarker testing strategies for hormone receptor-positive, HER2-negative metastatic breast cancer patients. The article discusses potential approaches to reshape treatment sequencing but contains no specific company, drug, or clinical trial data.